General Information
Version
5.2
Revision date
2025-12-06
Product name
Proligestone Formulation
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
+1-908-740-4000, +1-908-423-6000
Icons in SDS
Company Information
company name
MSD
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@msd.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H351, H360D
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H351 Suspected of causing cancer. H360D May damage the unborn child.
Prevention
P201 Obtain special instructions before use. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Storage
P405 Store locked up.
Hazardous Ingredients
Proligestone
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567) Carcinogenicity, Category 2 H351: Suspected of causing cancer. Reproductive toxicity, Category 1B H360D: May damage the unborn child.
